Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007688 | 0.93 | TLR7 (0.45) | TLR7TLR8ADORA2AADORA3ADORA1 | |
| SCHEMBL1008682 | 0.90 | TLR7 (0.44) | TLR7 | |
| SCHEMBL1060511 | 0.89 | ADORA2A (0.44) | TLR7TLR8ADORA2AADORA3ADORA1 | |
| SCHEMBL1010176 | 0.88 | ADORA2A (0.46) | TLR7TLR8ADORA2AADORA3ADORA1 | |
| SCHEMBL1008839 | 0.86 | TLR7 (0.40) | TLR7 | |
| SCHEMBL1704393 | 0.84 | TLR7 (0.41) | TLR7TLR8 | |
| SCHEMBL1923315 | 0.83 | APP (0.33) | APPPOLBHTR2AHTR2B | |
| SCHEMBL1061660 | 0.82 | TLR7 (0.43) | TLR7ADORA2AADORA3ADORA1APP | |
| SCHEMBL1008184 | 0.82 | TLR7 (0.41) | TLR7 | |
| SCHEMBL1056013 | 0.82 | TLR7 (0.47) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440245-B1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-06 | — | — | EP | claimed |
| EP-2512478-B1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-04-19 | — | — | EP | claimed |
| US-9517263-B2 | Benzonaphthyridine-containing vaccines | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-12-13 | — | — | US | claimed |
| US-9408907-B2 | Homogenous suspension of immunopotentiating compounds and uses thereof | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2016-08-09 | — | — | US | claimed |
| EP-2268618-B1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS AG (CH) | 2015-05-27 | — | — | EP | claimed |
| US-8895577-B2 | Compounds and compositions as TLR activity modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-11-25 | — | — | US | claimed |
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-26 | — | — | US | claimed |
| US-8466167-B2 | Compounds and compositions as TLR activity modulators | IRM LLC (BM) | 2013-06-18 | — | — | US | claimed |
| US-20130101629-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | claimed |
| EP-2512478-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2012-10-24 | — | — | EP | claimed |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | claimed |
| EP-2440245-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | Novartis AG (CH) | 2012-04-18 | — | — | EP | claimed |
| WO-2011084549-A1 | HOMOGENEOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2011-07-14 | — | — | WO | claimed |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-04-07 | — | — | US | claimed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | claimed |
| WO-2010144734-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | claimed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | claimed |
| US-10485761-B2 | Irradiated biodegradable polymer microparticles | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2019-11-26 | — | — | US | disclosed |
| WO-2010009277-A2 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253002-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | TLR7 3/4885TLR8 2/4885ADORA2A 596/4885 |
| US-20120263753-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | LY96, TLR3, GABRA4 | TLR7 7/4885TLR8 399/4885ADORA2A 1299/4885 |
| US-20130101629-A1 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF | CD14, ICOS, CD69 | TLR7 45/4885TLR8 650/4885ADORA2A 1019/4885 |
| US-10485761-B2 | Irradiated biodegradable polymer microparticles | EXOSC9, TNF, EXOSC5 | TLR7 192/4885TLR8 364/4885ADORA2A 4267/4885 |
| US-20110081365-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | TLR5, TLR8, TLR7 | TLR7 3/4885TLR8 2/4885ADORA2A 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.